N@N

Matthew Biegler Maintained (BPMC) at Buy with Increased Target to $90 on, Sep 6th, 2022

Matthew Biegler of Oppenheimer, Maintained "Blueprint Medicines Corporation" (BPMC) at Buy with Increased Target from $80 to $90 on, Sep 6th, 2022.

Matthew has made no other calls on BPMC in the last 4 months.

There are 10 other peers that have a rating on BPMC. Out of the 10 peers that are also analyzing BPMC, 3 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Andrew Berens of "SVB Leerink" Maintained at Hold with Decreased Target to $57 on, Thursday, August 18th, 2022
• Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $65 on, Tuesday, June 14th, 2022
• Christopher Raymond of "Piper Sandler" Maintained at Hold with Decreased Target to $65 on, Thursday, May 19th, 2022

These are the ratings of the 7 analyists that currently disagree with Matthew

---

• Eun Yang of "Jefferies" Maintained at Strong Buy with Increased Target to $84 on, Monday, August 22nd, 2022
• Bradley Canino of "Stifel" Maintained at Strong Buy with Increased Target to $100 on, Thursday, August 18th, 2022
• Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $80 on, Wednesday, August 17th, 2022
• Derek Archila of "Wells Fargo" Maintained at Sell with Increased Target to $41 on, Wednesday, August 17th, 2022
• Terence Flynn of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $143 on, Wednesday, August 3rd, 2022
• Dane Leone of "Raymond James" Maintained at Strong Buy with Decreased Target to $115 on, Wednesday, August 3rd, 2022
• David Lebowitz of "Citigroup" Downgraded from Hold to Strong Sell and Decreased Target to $41 on, Friday, June 10th, 2022

Contributing Sources

---